Collectively, these findings suggest that ASXL1MUT AML may be more appropriately classified as intermediate risk in the context of LIT+VEN-based therapy, with the depth of impact influenced by the specific LIT backbone.

P1, N=29, Recruiting, Institut Paoli-Calmettes | Not yet recruiting --> Recruiting

This case suggests that the combination of cladribine and low-dose rituximab may be an effective therapeutic strategy for classical HCL with TP53 abnormality, enabling deep molecular response and reversal of associated bone marrow fibrosis. Further prospective studies are warranted to validate these findings.

P4, N=30, Not yet recruiting, Aristotle University Of Thessaloniki

P1, N=3, Terminated, M.D. Anderson Cancer Center | N=40 --> 3 | Trial completion date: Dec 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Mar 2026; Slow participant enrollment

P2, N=60, Not yet recruiting, Uppsala University

P=N/A, N=30, Recruiting, The First Affiliated Hospital of Soochow University

P=N/A, N=70, Active, not recruiting, Ente Ospedaliero Cantonale, Bellinzona | Recruiting --> Active, not recruiting

Aggressive mastocytosis can rarely present with diffuse osteoblastic bone lesions mimicking metastatic disease.Elevated serum tryptase and histopathological confirmation are essential for diagnosis, even when KIT mutations are absent.Early recognition prevents unnecessary oncologic investigations and allows timely initiation of cytoreductive therapy.

P1, N=40, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027

P1/2, N=58, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Dec 2027

P=N/A, N=77, Completed, University Hospital, Rouen | Recruiting --> Completed